Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of talquetamab combinations versus EPd or PVd in relapsed or refractory multiple myeloma
CTR20241064Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of talquetamab, pomalidomide, teclistamab, elotuzumab, dexamethasone in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started May 2024; status: active.
02
Drugs
talquetamabpomalidomideteclistamabelotuzumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241064.